The goal of the study is to look at the relationship between how individuals with Sarcoidosis take the sarcoidosis medicines and how it affects the disease, to evaluate any factors that may make individuals not want to take the medicines, and to develop and refine ways to help support individuals with Sarcoidosis especially when it comes to the medicines. The overall hypothesis is higher medication adherence will be associated with better clinical outcomes in sarcoidosis. The investigators will enroll 150 patients with biopsy proven pulmonary sarcoidosis for at least one year who are on any oral treatment regimen for at least six months into a 12-month longitudinal study.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Change in King's Sarcoidosis Health Questionnaire (KSQ) score
Timeframe: Baseline, 6 months and 12 months
Change in St. George's Respiratory Questionnaire (SGRQ) score
Timeframe: Baseline, 6 months and 12 months
Change in Forced Expiratory Volume (FEV1) as assessed by Pulmonary Function Testing
Timeframe: Baseline, 6 months and 12 months
Change in Forced Vital Capacity (FVC) as assessed by Pulmonary Function Testing
Timeframe: Baseline, 6 months and 12 months
Change in Diffusing Capacity of Lung for Carbon Monoxide (DLCO) as assessed by Pulmonary Function Testing
Timeframe: Baseline, 6 months and 12 months
Change in 6-minute walk distance
Timeframe: Baseline, 6 months and 12 months
Change in Modified Medical Research Council Dyspnea Scale (MRC) score
Timeframe: Baseline, 6 months and 12 months
Change in Health Care Utilization (HCU) as assessed by the CRISP Database
Timeframe: 12 months prior to enrollment and the duration of the study for a total of 24 months